Xintela AB Interim Report January – June 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. THE GROUPSecond quarter 2024Income amounted to TSEK 4 (0).Loss before tax totalled TSEK 10,400 (loss: 18,401).Loss per share was SEK 0.02 (loss: 0.06). First half year 2024Income amounted to TSEK 303 (0).Loss before tax totalled TSEK 21,773 (loss: 34,244).Loss […]
Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients
Xintela and Region Östergötland have signed an agreement where Xintela will develop and establish a GMP process to isolate and quality assure autologous (patient-own) skin cells for the treatment of burns. The agreement is worth SEK 3.6 million. The process will form the basis for an approval from the Medical Products Agency for the Burn […]
Xintela AB Interim Report January – March 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2024 for the groupIncome amounted to TSEK 299 (0).Loss before tax totalled TSEK 11,372 (loss: 15,843).Loss per share was SEK 0.02 (loss: 0.05). First quarter 2024 for the parent companyIncome amounted to TSEK 299 (0).Loss before […]
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses
Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela’s equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in […]
Xintela AB publishes Annual Report 2023
Xintela AB (publ) announces that the company’s annual report for 2023 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]
Xintela AB Year-end Report 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter 2023 for the groupIncome amounted to TSEK 78 (0).Loss before tax totalled TSEK 12,175 (loss: 23,384).Loss per share was SEK 0.03 (loss: 0.09). The year 2023 for the groupIncome amounted to TSEK 78 (0).Loss before and […]
Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)
Xintela today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Xintela has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik […]
Xintela AB Interim Report January – September 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before tax totalled TSEK 11,953 (loss: 14,456).Loss per share was SEK 0.02 (loss: 0.11). First nine month 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]
Xintela AB Interim Report January – June 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 18,401 (loss: 18,942).Loss per share* was SEK 0.06 (loss: 0.21). First half year 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]
Xintela AB Interim Report January – March 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 15,843 (loss: 16,383).Loss per share* was SEK 0.05 (loss: 0.18). First quarter 2023 for the parent companyIncome amounted to TSEK 0 (0).Loss before […]
